Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2

ISBT COVID-19 Convalescent Plasma Working Group (see the Appendix)

研究成果: 雜誌貢獻文章同行評審

摘要

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the potential therapeutic value of early passive polyclonal immunotherapy using high-titer convalescent plasma (CCP). Human polyclonal hyperimmune immunoglobulin (HIG) has several advantages over CCP. Unlike CCP, HIG can provide standardized and controlled antibody content. It is also subjected to robust pathogen reduction rendering it virally safe and is purified by technologies demonstrated to preserve immunoglobulin neutralization capacity and Fc fragment integrity. This document provides an overview of current practices and guidance for the collection and testing of plasma rich in antibodies against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and its industrial fractionation for the manufacture of quality-assured and safe HIG. Considerations are also given to the production of HIG preparations in low- and middle-income countries.
原文英語
頁(從 - 到)125-132
頁數8
期刊Transfusion Medicine Reviews
36
發行號3
DOIs
出版狀態已發佈 - 7月 2022

ASJC Scopus subject areas

  • 血液學
  • 臨床生物化學
  • 生物化學(醫學)

指紋

深入研究「Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2」主題。共同形成了獨特的指紋。

引用此